Dublin, March 06, 2018 -- The "United States Biopsy Market, Volume & Forecast by Segments and Companies" report has been added to ResearchAndMarkets.com's offering
United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region
According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.
The World Cancer Report, produced by the WHO's specialized cancer agency and released on World Cancer Day, predicts new cancer cases will rise from an estimated 14 million annually in 2012 to 22 million within two decades. Over the same period, cancer deaths are predicted to rise from 8.2 million a year to 13 million.
On segment basis, Breast cancer biopsies accounts for the highest share in the United States Biopsy Market for the year 2017. While, in terms of Volume, Breast cancer biopsy has second highest share. Further, the report also covers the market aspects of Liver, Lung and Thyroid cancer biopsies. The Unites States Biopsy Market and Volume will experience a major growth during the forecast period owing to the increasing number of biopsy procedures and rising demand for minimally invasive procedures
All the 8 companies studied in the report have been studied from 4 points:
- Overview
- Business Strategy
- Merger & Acquisition
- Financial Insight
Segments Covered in the Report:
- Breast Cancer Biopsy
- Prostate Cancer Biopsy
- Lung Cancer Biopsy
- Liver Cancer Biopsy
- Thyroid Cancer Biopsy
Key Topics Covered:
1. Executive Summary
2. United States Biopsy Market & Volume (2008 - 2024)
3. Share Analysis - United States Biopsy (2008 - 2024)
4. Segments Analysis - United States Biopsy Market (2008 - 2024)
5. Growth Drivers
6. Challenges
7. Company Analysis
- B. Braun Melsungen AG
- Becton, Dickinson and Company
- C. R. Bard, Inc.
- Cardinal Health, Inc.
- FUJIFILM Holdings Corporation
- Hologic, Inc
- Medtronic plc.
- Olympus Corporation
For more information about this report visit https://www.researchandmarkets.com/research/rxddrz/united_states?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Medical Devices


Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



